Evusheld for COVID-19: How it works for people at high risk

A drug that can help prevent serious illness in people who are at the highest risk of developing complications COVID-19 Available from December 2021. But some people who could benefit from a breakthrough drug called Evusheld either haven’t heard of it or don’t realize they qualify for it. Experts say medical providers have also had trouble accessing and delivering Eusheld to people who need the potentially life-saving drug.

The US Food and Drug Administration (FDA) has granted Evusheld an Emergency Use Authorization (EUA) for people who cannot complete the immunization series due to a specific vaccine allergy and for people with weakened immune systems. Available vaccines work by stimulating the body’s immune response to produce protective antibodies, but some immunocompromised people may not develop these infection fighters after enough vaccinations — and that’s where Euskheld comes in.

How does Evusheld work?

Evusheld is a preventive medicine that contains two monoclonal antibodies (tixagwimab and cilgavimab), which are laboratory-made proteins that mimic the immune system’s ability to fight harmful pathogens. FDA. The coronavirus that causes COVID-19 has a protein on its surface that the virus uses to infect you. Eusheld’s monoclonal antibodies specifically help block these spike proteins from attaching to and entering human cells, according to the FDA.

Eusheld is given as two injections, usually in the thigh, one after the other. That’s considered a single dose of the medication to provide protection against exposure to COVID-19 for up to six months, according to the FDA. You must continue to receive injections every six months to maintain protection.

Evusheld is not a treatment for COVID-19, and it is not offered as an “add-on” form of protection for otherwise healthy, fully vaccinated people or as an alternative to vaccination unless you have a specific vaccine allergy. Priya Sampathkumar, MDInfectious disease Mayo Clinic in Rochester, Minnesota, tells SELF.

How effective is Evusheld?

Evusheld may reduce the risk of developing COVID-19 by up to 77% in unvaccinated adults. Clinical research Conducted by the drug manufacturer, AstraZeneca, and the US government. Participants included people who are at risk of not developing an adequate immune response from vaccination or who have been more exposed to COVID-19, including health care workers and people who work in meatpacking plants.

in february FDA updated its dosing recommendation for Evusheld, doubling its recommended amount when the EUA was first granted. According to the federal agency, a higher dose is more effective against certain omicron subtypes. “Doubling the dose is intended to overcome what we call immunogenicity,” says Dr. Sampathkumar. (In these variants, the spike proteins are often mutated, potentially allowing them to evade established immunity in some people. National Institutes of Health.)

Scientists are studying how well this shield protects against new subvariants as well. some earlier research suggests that it may offer some protection against the BA.5 variant currently dominant in the US, but FDA says that Eusheld is generally less effective against BA.4 and BA.5 Compared to BA.1, which dominated the number of COVID-19 cases in early 2022.

How should I take Eusheld?

To receive Evusheld, you must be at least 12 years old, weigh at least 88 pounds, and not be recently infected or knowingly exposed to COVID-19, according to the FDA. Only people who cannot produce protective amounts of antibodies after vaccination or people who are allergic to COVID vaccines or vaccine components are allowed.

Evusheld for COVID-19: How it works for people at high risk

Source link Evusheld for COVID-19: How it works for people at high risk

Back to top button